Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-Tenascin Radiolabeled Antibody Therapy - Related Studies

Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-Tenascin Radiolabeled Antibody Therapy (Glass-Art)

This study is currently recruiting participants.

Study NCT00615186. Last updated on October 1, 2008. Information provided by Bradmer Pharmaceuticals Inc.

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Glioblastoma Multiforme

2	Additional conditions recognized in this trial
		Glioblastoma

3	More general conditions related to this trial
		Astrocytoma
		Glioma
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms, Germ Cell and Embryonal
		Neoplasms, Glandular and Epithelial
		Neoplasms, Nerve Tissue
		Neoplasms, Neuroepithelial
		Neuroectodermal Tumors

4	Interventions listed in this trial
		Radiation Therapy + Temozolomide

5	Additional drug interventions recognized in this trial
		Immunoconjugates
		Temozolomide

6	More general drug interventions related to this trial
		Alkylating Agents
		Antineoplastic Agents
		Antineoplastic Agents, Alkylating
		Immunologic Factors
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

7	Sponsors listed in this trial
		Bradmer Pharmaceuticals Inc.
		ICON Clinical Research